Study to Evaluate the Natural History of Head and Neck Cancer Precursors in Taiwan
- Cancer of the mouth and throat is one of the most common cancers in Taiwan. This cancer develops over several years, beginning as white or red patches in the mouth or throat that become growths. It can also cause a condition that leads to rigidity of the cheeks. The growths can be identified when a doctor looks into a person s mouth. It is currently not clear why some people with abnormal growths progress to cancer while others do not. Researchers want to better understand why some patients with early abnormal growths get late abnormal growths. They also want to understand why some people get abnormal growths again, even after they receive treatment.
- To understand why some people with precancerous lesions in their mouth develop cancer while others do not.
- Adults 21 years and older, some with abnormal growths in the mouth, some without any, and some with head and neck cancer.
- Participants will visit a hospital in Taiwan 2 times.
- At the first visit, participants will answer questions about their health, lifestyle, and family medical history. A doctor will examine the participant s mouth and take a small piece of any growth they see. They will do this with a brush. They will also photograph the participant s mouth. Participants will also give blood and saliva samples, plus a small sample of a mouth rinse.
- Participants who are diagnosed with a late abnormal growth that is not cancer will return for a second visit. They will answer the same questions and undergo the same procedures as at the first study.
Head and Neck Neoplasms
|Study Design:||Observational Model: Cohort
Time Perspective: Other
|Official Title:||Natural History Of Oral Cancer Precursor Lesions: A Prospective Cohort Study|
- high-grade dysplasia/cancer [ Time Frame: ongoing ]
|Study Start Date:||November 17, 2013|
|Estimated Study Completion Date:||February 28, 2021|
|Estimated Primary Completion Date:||February 28, 2021 (Final data collection date for primary outcome measure)|
Oral cancers are ideal candidates for screening, early detection, and secondary prevention given the amenability for visual inspection and specimen collection and the availability of recognized precursors. Yet, there are currently no guidelines for screening, treatment, or follow-up of patients with oral cancer precursors, in part, owing to the current gaps in knowledge regarding the natural history of precursor lesions. We propose to conduct a prospective cohort study of patients with oral cancer precursors to address these knowledge gaps and to investigate novel etiologic factors.
In preparation for the cohort study, we recently conducted a pilot study in Taiwan, a country with high oral cancer incidence. This pilot was aimed to streamline field operations and collect preliminary data to aid in the design of the cohort study. As detailed in our concept, we successfully accomplished all of the goals of our pilot study, including successful recruitment and retention of patients as well as the collection of critical preliminary data.
Based on these efforts, we are seeking approval to conduct a prospective cohort study of 3000 patients with precursors to investigate the natural history of histologically-defined oral cancer precursor lesions and evaluate epidemiologic/ molecular predictors for progression. This prospective component will be complemented by cross-sectional comparisons of epidemiologic/molecular factors across 500 controls, 3000 precursors, and 500 cancers.
Please refer to this study by its ClinicalTrials.gov identifier: NCT02017288
|Contact: Anil K Chaturvedi, M.D.||(240) firstname.lastname@example.org|
|China Medical University Hospital||Recruiting|
|Taichung, Taiwan, 40402|
|Contact: Chien Yin-Chu Not Listed|
|National Taiwan University||Recruiting|
|Contact: Wang Chen-Ping Not Listed email@example.com|
|Linkou Chang Gung Memorial Hospital||Recruiting|
|Taoyuan City, Taiwan|
|Contact: Kang Chung-Jan (_03) 328-1200 firstname.lastname@example.org|
|Principal Investigator:||Anil K Chaturvedi, M.D.||National Cancer Institute (NCI)|